FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns an antibody-containing composition in the form of a solution with a pH of 4.5 to 6.5 for the treatment of diseases that develop and/or progress due to a decrease or deficiency in the activity of FVIII and/or activated blood coagulation factor VIII, which contains a bispecific antibody at a concentration of 20 to 180 mg/ml, in which the first polypeptide and the third polypeptide form a pair, and the second polypeptide and the fourth polypeptide form a pair, wherein the first polypeptide contains an H chain, containing the amino acid sequences of CDRs 1, 2 and 3 of the H-chain having SEQ ID NO: 1, 2 and 3 (CDR of the H-chain Q499), respectively, the second polypeptide contains the H-chain containing the amino acid sequences of CDRs 1, 2 and 3 H- chains having SEQ ID NO: 4, 5 and 6 (H chain CDR J327), respectively, and the third polypeptide and the fourth polypeptide contain a common L chain containing the amino acid sequences of the L chain CDRs 1, 2 and 3 of SEQ ID NO: 7 8 and 9 (CDR of L-chain L404), respectively, histidine / aspartate buffer at a concentration of 20 mM, poloxamer 188 at a concentration of 0.2 to 1 mg / ml, and arginine at a concentration of 100 to 300 mM. The group of inventions also relates to a method for stabilizing an antibody in an antibody-containing composition in the form of a solution, which includes the addition of histidine/aspartate buffer, poloxamer 188 and arginine to the solution, a method for suppressing the formation of antibody aggregates in an antibody-containing composition in the form of a solution, which includes the addition of histidine / aspartate buffer, poloxamer 188 and arginine to solution.
EFFECT: group of inventions provides improved stability of antibodies in solution.
12 cl, 9 ex, 2 dwg, 9 tbl
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION OF ANTI-TRBV9 ANTIBODY AND USE THEREOF | 2022 |
|
RU2826886C1 |
PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII | 2015 |
|
RU2721910C2 |
MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
ANTIBODY WHICH IS CAPABLE OF NEUTRALIZING A SUBSTANCE HAVING AN ACTIVITY OF AN ALTERNATIVE COAGULATION FACTOR FUNCTION VIII (FVIII) | 2015 |
|
RU2737145C2 |
COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
METHOD FOR MEASURING REACTIVITY OF FVIII | 2015 |
|
RU2752595C2 |
ANTIBODIES DIRECTED AGAINST THE INTERLEUKIN 36 (IL-36R) RECEPTOR | 2016 |
|
RU2745898C2 |
ANTI-CD38 ANTIBODIES AND FORMULATIONS | 2020 |
|
RU2826957C2 |
COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE | 2018 |
|
RU2779430C2 |
Authors
Dates
2021-05-19—Published
2017-04-27—Filed